Detection of lymph node micrometastases in colorectal cancer

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 2, 2003, Pages 125-132

  Nordgard O ^a   Aloysius, T A ^a   Todnem, K ^a   Heikkila R ^a   Ogreid D ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AVIDIN; BIOTIN; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; DNA MARKER; EOSIN; EPITHELIAL MEMBRANE ANTIGEN; FLUOROURACIL; HEMATOXYLIN; PEROXIDASE;

ADJUVANT CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CAUSE OF DEATH; COLORECTAL CANCER; DISSEMINATED CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; METHODOLOGY; MICROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCANDINAVIA; TUMOR RECURRENCE; UNITED STATES;

EID: 0037299938     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000591     Document Type: Review

References (89)

1. Statistics Norway. Causes of death, 1999; 2001.
2. The National Board of Health and Welfare. Cancer incidence in Sweden 1999; 2001.
3. Statbank Denmark. Cancer deaths, 1993.
4. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
5. Cohen AM, Tremiterra S, Candela F, Thaler HT, Sigurdson ER. Prognosis of node-positive colon cancer. Cancer 1991;67:1859-61.
6. Fielding P. Staging systems. In: Cohen A, Winawer S, editors, Cancer of the colon, rectum and anus. New York: McGraw-Hill; 1995:207-15.
7. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-94.
8. Hammond ME, Fitzgibbons PL, Compton CC, Grignon DJ, Page DL, Fielding LP, et al. College of American Pathologists Conference XXXV: solid tumor prognostic factors - which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. Arch Pathol Lab Med 2000;124:958-65.
9. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 1998;41:1033-49.
10. Huvos AG, Hurter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44-6.
11. Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol 1998;67:194-202.
12. Lacroix J, Doeberitz MK. Technical aspects of minimal residual disease detection in carcinoma patients. Semin Surg Oncol 2001;20:252-64.
13. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
14. Cutait R, Alves VA, Lopes LC, Cutait DE, Borges JL, Singer J, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-20.
15. Jeffers MD, O'Dowd GM, Mulcahy H, Stagg M, O'Donoghue DP, Toner M. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994;172:183-7.
16. Adell G, Boeryd B, Franlund B, Sjodahl R, Hakansson L. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Dukes' B colorectal carcinoma: an immunohistochemical study. Eur J Surg 1996;162:637-42.
17. Oberg A, Stenling R, Tavelin B, Lindmark G. Are lymph node micrometastases of any clinical significance in Dukes' Stages A and B colorectal cancer? Dis Colon Rectum 1998;41:1244-9.
18. Tschmelitsch J, Klimstra DS, Cohen AM. Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol 2000;7:601-8.
19. Noura S, Yamamoto H, Miyake Y, Kim B, Takayama O, Seshimo I, Ikenaga M, Ikeda M, Sekimoto M, Matsuura N, Monden M. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759-67.
20. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr. Identification of occult micrometastases in pericolic lymph nodes of Dukes' B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-9.
21. Isaka N, Nozue M, Doy M, Fukao K. Prognostic significance of perirectal lymph node micrometastases in Dukes' B rectal carcinoma: an immunohistochemical study by CAM5.2. Clin Cancer Res 1999;5:2065-8.
22. Yasuda K, Adachi Y, Shiraishi N, Yamaguchi K, Hirabayashi Y, Kitano S. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001;8:300-4.
23. Pantel K, von Knebel Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol 2000;12:95-101.
24. Rosenberg R, Hoos A, Mueller J, Baier P, Stricker D, Werner M, et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol 2002;20:1049-55.
25. Hayashi N, Ito I, Yanagisawa A, Kato Y, Nakamori S, Imaoka S, et al. Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-9.
26. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
27. Dennis Lo YM, editor. Clinical applications of PCR. Totowa, NJ: Humana Press; 1998:61-9.
28. Burmer GC, Rabinovitch PS, Loeb LA. Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing. Cancer Res 1989;49:2141-6.
29. Burmer GC, Rabinovitch PS, Loeb LA. Frequency and spectrum of c-Ki-ras mutations in human sporadic colon carcinoma, carcinomas arising in ulcerative colitis, and pancreatic adenocarcinoma. Environ Health Perspect 1991;93:27-31.
30. Capella G, Cronauer-Mitra S, Pienado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991;93:125-31.
31. Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 1999;5:2450-4.
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6.
33. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N, et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 1991;6:1079-83.
34. Ronai Z, Minamoto T. Quantitative enriched PCR (QEPCR), a highly sensitive method for detection of K-ras oncogene mutation. Hum Mutat 1997;10:322-5.
35. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 1999;59:5169-75.
36. Takeda S, Ichii S, Nakamura Y. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA). Hum Mutat 1993;2:112-7.
37. Kirby GM, Batist G, Fotouhi-Ardakani N, Nakazawa H, Yamasaki H, Kew M, et al. Allele-specific PCR analysis of p53 codon 249 ACT transversion in liver tissues from patients with viral hepatitis. Int J Cancer 1996;68:21-5.
38. Hashimoto T, Kobayashi Y, Ishikawa Y, Tsuchiya S, Okumura S, Nakagawa K, et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res 2000;60:6472-8.
39. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118-26.
40. Hibi K, Nakayama H, Yamazaki T, Takase T, Taguchi M, Kasai Y, et al. Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 2001;94:429-31.
41. Kell MR, Winter DC, O'Sullivan GC, Shanahan F, Redmond HP. Biological behaviour and clinical implications of micrometastases. Br J Surg 2000;87:1629-39.
42. Ruud P, Fodstad O, Hovig E. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells. Int J Cancer 1999;80:119-25.
43. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
44. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;71:278-81.
45. Gunn J, McCall JL, Yun K, Wright PA. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction. Lab Invest 1996;75:611-6.
46. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998;16:2632-40.
47. Yun K, Merrie AE, Gunn J, Phillips LV, McCall JL. Keratin 20 is a specific marker of submicroscopic lymph node metastases in colorectal cancer: validation by K-RAS mutations. J Pathol 2000;191:21-6.
48. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer 1999;81:870-3.
49. Bustin SA, Gyselman VG, Williams NS, Dorudi S. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999;79:1813-20.
50. Futamura M, Takagi Y, Koumura H, Kida H, Tanemura H, Shimokawa K, et al. Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoembryonic antigen and cytokeratin 20. J Surg Oncol 1998;68:34-40.
51. Rosenberg R, Hoos A, Mueller J, Nekarda H. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Br J Cancer 2000;83:1323-9.
52. Miyake Y, Yamamoto H, Fujiwara Y, Ohue M, Sugita Y, Tomita N, et al. Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin Cancer Res 2001;7:1350-7.
53. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
54. Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1995;55:3417-20.
55. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-8.
56. Ghossein RA. Detection of carcinoembryonic antigen messenger RNA in lymph nodes from patients with colorectal cancer. N Engl J Med 1998;339:1642-3.
57. Fulle HJ, Garbers DL. Guanylyl cyclases: a family of receptor-linked enzymes. Cell Biochem Funct 1994;12:157-65.
58. Hughes JM, Murad F, Chang B, Guerrant RL. Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature 1978;271:755-6.
59. Guerrant RL, Hughes JM, Chang B, Robertson DC, Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: studies of tissue specificity, potential receptors, and intermediates. J Infect Dis 1980; 142: 220-8.
60. Rao MC, Guandalini S, Smith PL, Field M. Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim Biophys Acta 1980;632:35-46.
61. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA 1996;93:14827-32.
62. Schulz S, Chrisman TD, Garbers DL. Cloning and expression of guanylin. Its existence in various mammalian tissues. J Biol Chem 1992;267:16019-21.
63. Laney DW, Jr., Mann EA, Dellon SC, Perkins DR, Giannella RA, Cohen MB. Novel sites for expression of an Escherichia coli heat-stable enterotoxin receptor in the developing rat. Am J Physiol 1992;263:G816-21.
64. Fava TA, Desnoyers R, Schulz S, Park J, Weinberg D, Mitchell E, et al. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J Clin Oncol 2001;19:3951-9.
65. Cagir B, Gelmann A, Park J, Fava T, Tankelevitch A, Bittner EW, et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann Intern Med 1999;131:805-12.
66. Waldman SA, Cagir B, Rakinic J, Fry RD, Goldstein SD, Isenberg G. et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis Colon Rectum 1998;41:310-5.
67. Tien YW, Chang KJ, Jeng YM, Lee PH, Wu MS, Lin JT, et al. Tumor angiogenesis and its possible role in intravasation of colorectal epithelial cells. Clin Cancer Res 2001;7:1627-32.
68. Waldman SA, Barber M, Pearlman J, Park J, George R, Parkinson SJ. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol Biomarkers Prev 1998;7:505-14.
69. Ho SB, Niehans CA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
70. Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res 1995;55:2681-90.
71. Hanski C, Hofmeier M, Schmitt-Graff A, Riede E, Hanski ML, Borchard F, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 1997;182:385-91.
72. Pinto-de Sousa J, David L, Reis CA, Gomes R, Silva L, Pimenta A. Mucins MUC1, MUC2, MUC5AC and MUC6 expression in the evaluation of differentiation and clinico-biological behaviour of gastric carcinoma. Virchows Arch 2002;440:304-10.
73. Bernini A, Spencer M, Frizelle S, Madoff RD, Willmott LD, McCormick SR, et al. Evidence for colorectal cancer micrometastases using reverse transcriptase-polymerase chain reaction analysis of MUC2 in lymph nodes. Cancer Detect Prev 2000;24:72-9.
74. Hanski C, Riede E, Gratchev A, Foss HD, Bohm C, Klussmann E, et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab Invest 1997;77:685-95.
75. Ichikawa Y, Ishikawa T, Momiyama N, Yamaguchi S, Masui H, Hasegawa S, et al. Detection of regional lymph node metastases in colon cancer by using RT-PCR for matrix metalloproteinase 7, matrilysin. Clin Exp Metastasis 1998;16:3-8.
76. Aihara T, Fujiwara Y, Miyake Y, Okami J, Okada Y, Iwao K, et al. Mammaglobin B gene as a novel marker for lymph node micrometastasis in patients with abdominal cancers. Cancer Lett 2000;150:79-84.
77. Bilchik AJ, Saha S, Wiese D, Stonecypher JA, Wood TF, Sostrin S, et al. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol 2001;19:1128-36.
78. Niiyama H, Mizumoto K, Sato N, Nagai E, Mibu R, Fukui T, et al. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001;96:1895-900.
79. Strausberg RL. The Cancer Genome Anatomy Project: new resources for reading the molecular signatures of cancer. J Pathol 2001;195:31-40.
80. Scheurle D, DeYoung MP, Binninger DM, Page H, Jahanzeb M, Narayanan R. Cancer gene discovery using digital differential display. Cancer Res 2000;60:4037-43.
81. Baranova AV, Lobashev AV, Ivanov DV, Krukovskaya LL, Yankovsky NK, Kozlov AP. In silico screening for tumour-specific expressed sequences in human genome. FEBS Lett 2001;508:143-8.
82. van Eekelen JA, Shammas FV, Wee L. Heikkila R, Osland A. Quantitative analysis of cytokeratin 20 gene expression using RT-PCR and capillary electrophoresis with fluorescent DNA detection. Clin Biochem 2000;33:457-64.
83. Esser S, Reilly WT, Riley LB, Eyvazzadeh C, Arcona S. The role of sentinel lymph node mapping in staging of colon and rectal cancer. Dis Colon Rectum 2001;44:850-4.
84. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
85. Saha S, Wiese D, Badin J, Beutler T, Nora D, Ganatra BK, et al. Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. Ann Surg Oncol 2000;7:120-4.
86. Bilchik AJ, Giuliano A, Essner R, Bostick P, Kelemen P, Foshag LJ, et al. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am 1998;4:351-8.
87. Paramo JC, Summerall J, Wilson C, Cabral A, Willis I, Wodnicki H, et al. Intraoperative sentinel lymph node mapping in patients with colon cancer. Am J Surg 2001;182:40-3.
88. Bilchik AJ, Nora D, Tollenaar RA, van de Velde CJ, Wood T, Turner R, et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer 2002;38:977-85.
89. Merrie AE, Phillips LV, Yun K, McCall JL. Skip metastases in colon cancer: assessment by lymph node mapping using molecular detection. Surgery 2001;129:684-91.